

**PEDIATRIC INFLUENZA VACCINE**  
Available from the Idaho Immunization Program  
for the 2016-2017 Season\*

VACCINE	TRADE NAME	MANUFACTURER	PRESENTATION	MERCURY CONTENT (mcg Hg/0.5mL dose)	AGE GROUP	NUMBER OF DOSES	ROUTE	NDC	CPT CODE	CVX CODES (for electronic exports)
IIV4	Fluzone® Quadrivalent	Sanofi Pasteur	0.25mL pre-filled syringe	0	6-35 months	1 or 2	IM**	49281-0516-25	90685	161
			0.5mL pre-filled syringe	0	≥ 36 months	1 or 2	IM**	49281-0416-50	90686	150
			0.5mL single dose vial	0	≥ 36 months	1 or 2	IM**	49281-0416-10	90686	150
			5.0mL multi-dose vial	25	≥ 6 months	1 or 2	IM**	49281-0625-15	90688	158
IIV4	Fluarix® Quadrivalent	GlaxoSmithKline	0.5mL pre-filled syringe	0	≥ 3 years	1 or 2	IM**	58160-0905-52	90686	150
	FluLaval® Quadrivalent		5.0mL multi-dose vial	<25	≥ 3 years	1 or 2	IM**	58160-0903-11	90688	158
IIV4	Flucelvax® Quadrivalent	Seqirus	0.5mL pre-filled syringe	0	≥ 4 years	1 or 2	IM**	70461-0200-01	90674	171

Abbreviations: IIV4=Inactivated Influenza Vaccine, Quadrivalent; IM=intramuscular injection.

\* Immunization providers should check Food and Drug Administration--approved prescribing information for 2016--17 influenza vaccines for the most complete and updated information, including (but not limited to) indications, contraindications, and precautions. Package inserts for US-licensed vaccines are available at <http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm093833.htm>

\*\* For adults and older children, the recommended site of vaccination is the deltoid muscle. The preferred site for infants and young children is the anterolateral aspect of the thigh. Specific guidance regarding site and needle length for intramuscular administration may be found in the Advisory Committee on Immunization Practices' General Recommendations on Immunization (available at <http://www.cdc.gov/mmwr/preview/mmwrhtml/rr6002a1.htm>).

For additional information regarding 2016-2017 seasonal influenza vaccine please refer to the Centers for Disease Control and Prevention's Morbidity and Mortality Weekly Report / Recommendations and Reports / August 26, 2016 / 65(5);1-54 or visit [https://www.cdc.gov/mmwr/volumes/65/rr/rr6505a1.htm?s\\_cid=rr6505a1\\_w](https://www.cdc.gov/mmwr/volumes/65/rr/rr6505a1.htm?s_cid=rr6505a1_w)

